Methods for delivering antibodies to the fetal circulation to reduce severity or incidence of fetal or neonatal respiratory syncytial virus (RSV) disease

Intra-amniotic delivery of RSV-targeting antibodies minimizes neonatal RSV infection by delivering antibodies to the fetal circulation, addressing the limitations of current prevention methods and enhancing early protection against RSV.

WO2026236263A1PCT designated stage Publication Date: 2026-11-12CHILDRENS MEDICAL CENT CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026745
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current methods for preventing respiratory syncytial virus (RSV) infection in newborns are invasive or limited by poor placental transfer, lacking effective strategies for the early neonatal period.

Method used

Minimally invasive intra-amniotic delivery of antibodies or antigen-binding fragments to the fetal circulation, specifically targeting RSV antigens, to reduce the propensity and severity of RSV infection.

Benefits of technology

Reduces the incidence and severity of RSV infection in neonates by administering antibodies or antigen-binding polypeptides to the amniotic fluid, providing protection before birth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000036_0000
    Figure 00000036_0000
  • Figure 00000037_0000
    Figure 00000037_0000
Patent Text Reader

Abstract

Compositions and methods for delivering antibodies to the fetal circulation for reducing the propensity of a fetus or neonate to be infected with RSV and / or reducing the severity of respiratory syncytial virus (RSV) disease in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Atorney Docket No.: 167705-038301 / PCT

[0002] Electronic Deposit Date: May 5, 2026

[0003] METHODS FOR DELIVERING ANTIBODIES TO THE FETAL CIRCULATION TO REDUCE SEVERITY OR INCIDENCE OF FETAL OR NEONATAL RESPIRATORY SYNCYTIAL VIRUS (RSV) DISEASE

[0004] CROSS REFERENCE TO RELATED APPLICATION

[0005] The present application claims priority to and the benefit of U.S. App. No. 63 / 800,019, filed May 5, 2025, the entirety of which is hereby incorporated by reference.

[0006] BACKGROUND

[0007] Delivery of immunoglobulins directly to the fetus is invasive and can be prone to adverse effects, while indirect delivery via the mother is limited by poor and selective placental transfer. Respiratory syncytial virus (RSV) disease remains highly prevalent in infants and children and tends to be particularly dangerous for newborns. There is currently no effective strategy for the prevention of RSV in that patient population, especially in the very early neonatal period when children cannot be vaccinated. Thus, there remains a need for minimally invasive methods for reducing the propensity of newborns to become infected with RSV.

[0008] SUMMARY

[0009] As described below, the present disclosure features minimally invasive methods for delivering antibodies (e.g., via intra-amniotic delivery) to the fetal circulation to be used for reducing the propensity of an neonate to be infected with RSV, or reducing the severity of respiratory syncytial virus (RSV) disease in a neonatal subject. In one aspect, the present disclosure features a method for reducing respiratory syncytial virus (RSV) morbidity in a fetus or neonate. The method involves administering to the amniotic fluid surrounding the fetus an antibody or antigen binding fragment thereof that specifically binds respiratory syncytial virus (RSV) where the fetus or newborn has or has a propensity to develop RSV and the method reduces the infection and / or reduces the propensity for infection with of the neonate with RSV.

[0010] In embodiments, the administration is associated with a reduction in incidence of neonatal infection and / or severity of infection.

[0011] In one aspect, the present disclosure features a method for reducing the propensity of a fetal or neonatal subject to become infected with a respiratory syncytial virus (RSV) or reducing the severity of a respiratory syncytial virus (RSV) infection or symptoms thereof in a fetal or neonatal subject. The method involves administering to the amniotic fluid surrounding theAtorney Docket No.: 167705-038301 / PCT

[0012] Electronic Deposit Date: May 5, 2026

[0013] subject as a fetus an antigen-binding polypeptide, or antigen-binding fragment thereof, capable of specifically binding an RSV antigen, thereby reducing the propensity of the fetal or neonatal subject to become infected with a respiratory syncytial virus (RSV) or reducing the severity of a respiratory syncytial virus (RSV) infection or symptoms thereof in the fetal or neonatal subject. The subject has or has a propensity to develop a perinatal RSV infection.

[0014] In another aspect, the present disclosure features a kit suitable for use in carrying out the method. The kit contains the antigen-binding polypeptide, or antigen-binding fragment thereof, of any aspect of the disclosure, or embodiments thereof, and a container.

[0015] In any aspect of the disclosure, or embodiments thereof, the RSV antigen is an RSV F protein or a fragment thereof. In any aspect of the disclosure, or embodiments thereof, the antigen-binding polypeptide, or antigen-binding fragment thereof, is administered by intra-amniotic injection. In any aspect of the disclosure, or embodiments thereof, the antigen-binding polypeptide, or antigen-binding fragment thereof, is derived from an IgA, IgD, IgE, IgG, IgM, IgY and / or IgW antibody. In any aspect of the disclosure, or embodiments thereof, the antigenbinding polypeptide is a human antibody. In any aspect of the disclosure, or embodiments thereof, the antigen-binding polypeptide is RSV-binding polypeptide A or RSV-binding polypeptide B.

[0016] In any aspect of the disclosure, or embodiments thereof, the antigen-binding polypeptide contains one or more of the following complementarity determining regions (CDRs): VH CDR1: DYIIN; VH CDR2: GIIPVLGTVHYGPKFQ; VH CDR3: ETALVVSETYLPHYFD; VL CDR1: QASQDIVNYLN; VL CDR2: VASNLET; and VL CDR3: QQYDNLPLT. In any aspect of the disclosure, or embodiments thereof, the antigen-binding polypeptide contains an amino acid sequence having at least about 85% identity to the following variable heavy chain (VH) amino acid sequence:

[0017] QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKF QGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSS. In any aspect of the disclosure, or embodiments thereof, the antigen-binding polypeptide contains an amino acid sequence having at least about 85% identity to the following heavy chain (HC) amino acid sequence:

[0018] QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKF QGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQAtorney Docket No.: 167705-038301 / PCT

[0019] Electronic Deposit Date: May 5, 2026 DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPGK. In any aspect of the disclosure, or embodiments thereof, the antigen-binding polypeptide contains an amino acid sequence having at least 85% identity to the following variable light chain (VL) amino acid sequence:

[0020] DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLJETGVPSRFSG SGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIKRTV. In any aspect of the disclosure, or embodiments thereof, the antigen-binding polypeptide contains an amino acid sequence having at least about 85% identity to the following light chain (LC) amino acid sequence:

[0021] DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLJETGVPSRFSG SGSGTDFSLTISSLQPEDVATYYCQQYDNLPLJTFGGGTKVEIKRTVAAPSVFIFPPSDEQLJKSG TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACE VTHQGLS S PVTKS FNRGEC.

[0022] In any aspect of the disclosure, or embodiments thereof, the antigen-binding polypeptide, or antigen-binding fragment thereof, is detectable in the subject at one week following birth. In any aspect of the disclosure, or embodiments thereof, the antigen-binding polypeptide, or antigen binding fragment thereof, is detectable in blood and / or lung tissue of the subject at one week following birth.

[0023] In any aspect of the disclosure, or embodiments thereof, the method involves administering the antigen-biding polypeptide, or antigen-binding fragment thereof, to the amniotic fluid prior to or during labor. In any aspect of the disclosure, or embodiments thereof, a first or sole administration of the antigen-biding polypeptide, or antigen-binding fragment thereof, to the amniotic fluid is made during labor. In any aspect of the disclosure, or embodiments thereof, the subject has increased an increased propensity to become infected with RSV, where the increase results from an increase in incidence or predicted increase in incidence of RSV disease at a location where the subject is or will be disposed, and / or during a time period within which the subject is expected to be born.

[0024] In any aspect of the disclosure, or embodiments thereof, the subject is a mammal. In any aspect of the disclosure, or embodiments thereof, the subject is a human. In any aspect of the disclosure, or embodiments thereof, the human subject is a fetus between 7-9 months of term. In any aspect of the disclosure, or embodiments thereof, where the human subject is a neonate.

[0025] In any aspect of the disclosure, or embodiments thereof, the administration is associated with the presence of and / or an increase in levels of the antigen-binding polypeptide, or antigen-Atorney Docket No.: 167705-038301 / PCT

[0026] Electronic Deposit Date: May 5, 2026

[0027] binding fragment thereof, in the serum of the subject. In any aspect of the disclosure, or embodiments thereof, the administration is associated with the presence of and / or an increase in levels of the, antigen-binding polypeptide, or antigen-binding fragment thereof, in a tissue of the subject.

[0028] In any aspect of the disclosure, or embodiments thereof, the method further involves determining that the mother of the subject is likely to have an adverse response to the antigenbinding polypeptide, or antigen-binding fragment thereof, and the method does not involve introducing the antigen-binding polypeptide, or antigen-binding fragment thereof, to the blood of the mother of the subject at harmful levels.

[0029] The present disclosure provides methods for delivering antibodies to the fetal circulation to be used for reducing the propensity of a fetus or neonate to be infected with RSV and / or reducing the severity of RSV disease in a subject (e.g., in a fetal subject, a neonatal subject, or a perinatal subject). Compositions and articles defined by the present disclosure were isolated or otherwise manufactured in connection with the examples provided below. Other features and advantages of the present disclosure will be apparent from the detailed description, and from the claims.

[0030] Definitions

[0031] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this present disclosure belongs. The following references provide one of skill with a general definition of many of the terms used in this disclosure: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise.

[0032] By “administer” is meant giving, supplying, dispensing, delivering, or applying a composition, agent, therapeutic and the like to a subject, or applying or bringing the composition and the like into contact with the subject. In some embodiments, administration is intra-amniotic administration (e.g., transamniotic fetal immunotherapy (TRAFIT)).

[0033] By “agent” is meant any small molecule chemical compound, nucleic acid molecule, or polypeptide, or fragments thereof. In various embodiments, the agent is an antibody (e.g., an antibody capable of specifically binding an RSV antigen) or an antigen binding fragment thereof.Atorney Docket No.: 167705-038301 / PCT

[0034] Electronic Deposit Date: May 5, 2026

[0035] In some cases, the agent is an antibody selected from RSV-binding polypeptide A and / or RSV-binding polypeptide B.

[0036] By “ameliorate” is meant decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease.

[0037] By “alteration” is meant a change in the structure, expression levels or activity of a gene or polypeptide as detected by standard art known methods, such as those described herein. The alteration can be an increase or a decrease. As used herein, non-limiting examples of alterations include a 5% change, 10% change, a 25% change, a 40% change, or a 50% or greater change in a measured quantity, such as expression levels, incidence of infection, mortality, or protein levels.

[0038] By “analog” is meant a molecule that is not identical, but has analogous functional or structural features. For example, a polypeptide analog retains the biological activity of a corresponding naturally occurring polypeptide, while having certain biochemical modifications that enhance the analog’s function relative to a naturally occurring polypeptide. Such biochemical modifications could increase the analog’s protease resistance, membrane permeability, or half-life, without altering, for example, ligand binding. An analog may include an unnatural amino acid.

[0039] As used herein, the term “antibody” refers to an immunoglobulin molecule, or antigen binding fragment thereof, that specifically binds to, or is immunologically reactive with, a particular antigen (e.g., an RSV polypeptide). Accordingly, antibodies described herein include polyclonal, monoclonal, pooled, genetically engineered and otherwise modified forms of antibodies, including but not limited to chimeric antibodies, humanized antibodies, heteroconjugate antibodies (e.g., bi- tri- and quad-specific antibodies, diabodies, triabodies, and tetrabodies), and antigen-binding fragments of antibodies, including e.g., Fab’, F(ab’)2, Fab, Fv, rlgG, and scFv fragments, as well as engineered antibodies, which include CrossMabs (e.g., CrossMabFabs, CrossMabCH1'CLand CrossMabVH'VLformats). Moreover, unless otherwise indicated, the term “monoclonal antibody” (mAb) is meant to include both intact molecules as well as antibody fragments (such as, for example, Fab and F(ab’)2 fragments) that are capable of specifically binding to a target protein. Fab and F(ab’)2 fragments lack the Fc fragment of an intact antibody, clear more rapidly from the circulation of the animal, and may have less nonspecific tissue binding than an intact antibody (see Wahl et al., J. Nucl. Med. 24:316, 1983; incorporated herein by reference). In one embodiment, an antibody is a biparatopic antibody. An antibody may be a monoclonal antibody.

[0040] Antibody structure is well known in the art. Briefly, the variable (V) regions or domains of antibody heavy (H) and light (L) chains contain Complementarity-Determining RegionsAtorney Docket No.: 167705-038301 / PCT

[0041] Electronic Deposit Date: May 5, 2026

[0042] (CDRs), which bind to specific antigens or immunogens (e.g., protein antigens or immunogens). CDRs are situated within framework (FR) sequences of the V regions of the heavy (VH) and light chains (VL) of an antibody. CDRs are the most variable parts of antibodies and are critical components in the diversity of antigen specificities of antibodies produced by B lymphocytes. In general, three CDRs (CDR1, CDR2 and CDR3) are arranged consecutively in a V domain of an antibody. Each of an antibody’s H and L chains contains three CDRs that bind to an antigen or target protein such as an RSV antigen in the context of four framework (FR) regions, as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Because most of the sequence variability associated with immunoglobulins and antigen binding is found in the CDRs, these regions are sometimes referred to as hypervariable regions. Typically, CDR1, CDR2 and CDR3 of an antibody contribute to and / or do not interfere with antigen binding.

[0043] Antibodies (immunoglobulins) comprise two heavy chains linked together by disulfide bonds, and two light chains, with each light chain being linked to a respective heavy chain by disulfide bonds in a “Y” shaped configuration. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains (CH). Each light chain has a variable domain (VL) at one end and a constant domain (CL) at its other end. The variable domain of the light chain (VL) is aligned with the variable domain of the heavy chain (VL), and the light chain constant domain (CL) is aligned with the first constant domain of the heavy chain (CHI). The variable domains of each pair of light and heavy chains form the antigen binding site. The isotype of the heavy chain (gamma, alpha, delta, epsilon or mu) determines the immunoglobulin class (IgG, IgA, IgD, IgE or IgM, respectively). The light chain is either of two isotypes (kappa (K) or lambda (1)) found in all antibody classes.

[0044] By “antigen” is meant an agent to which an antibody specifically binds. In an embodiment, the antigen is an RSV protein (e.g., an RSV F protein) or a fragment thereof.

[0045] Exemplary antigens include small molecules, carbohydrates, proteins, and polynucleotides. The term “antigen-binding fragment,” as used herein, refers to one or more portions or fragments of an antibody that retain the ability to specifically bind to a target antigen. In some embodiments, the target antigen is an RSV protein (e.g., an RSV F protein).

[0046] As used herein, the term “complementarity determining region (CDR)” refers to noncontiguous antigen-binding sites within an antibody. In various embodiments, amino acids in a CDR are identified using sequence or structure based methods. These particular regions have been described by Kabat et al., J. Biol. Chem. 252:6609-6616, 1977 and Kabat, et al., Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, 1991; by Chothia et al., (J. Mol. Biol. 196:901-917,Atorney Docket No.: 167705-038301 / PCT

[0047] Electronic Deposit Date: May 5, 2026

[0048] 1987), and by MacCallum et al., (J. Mol. Biol. 262:732-745, 1996) where the definitions include overlapping or subsets of amino acid residues when compared against each other. In certain embodiments, a CDR is defined by Kabat based on sequence comparisons. In various embodiments, a CDR is defined using a numbering scheme selected from Chothia, Martin (Enhanced Chothia or AbM), Kabat, Honnegeer (AHo), Contact, and IMGT.

[0049] As used in this disclosure and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended. This wording indicates that specified elements, features, components, and / or method steps are present, but does not exclude the presence of other elements, features, components, and / or method steps. Any embodiments specified as “comprising” a particular component(s) or element(s) are also contemplated as “consisting of’ or “consisting essentially of’ the particular component(s) or element(s) in some embodiments. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the present disclosure, and vice versa. Furthermore, compositions of the present disclosure can be used to achieve methods of the present disclosure.

[0050] “Detect” refers to identifying the presence, absence or amount of an analyte to be detected. In an embodiment, the analyte is an antibody. In some embodiments, the analyte is an antibody that specifically binds an antigen derived from a pathogen (e.g., an RSV F protein). In some embodiments, the analyte is an RSV antigen.

[0051] By “disease” is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. In various embodiments, the disease is a respiratory syncytial virus (RSV) infection.

[0052] By “effective amount” is meant the amount of an agent required to ameliorate the symptoms of a disease relative to an untreated patient. The effective amount of active compound(s) used to practice the various aspects or embodiments of the present disclosure for therapeutic treatment of a disease varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an “effective” amount. In some embodiments, an effective amount of a composition provided herein is an amount capable of reducing the propensity of a fetus or neonate to be infected with RSV and / or reducing the severity of respiratory syncytial virus (RSV) disease in a subject. In one embodiment, an effective amount is the amount sufficient to reduce the propensity of a fetusAtorney Docket No.: 167705-038301 / PCT

[0053] Electronic Deposit Date: May 5, 2026

[0054] or neonate to become infected with RSV. In another embodiment, an effective amount is the amount sufficient to reduce the severity of an RSV infection in a fetus or neonate infected with RSV.

[0055] By “fetus” is meant an unborn subject. In embodiments, the subject is a human child. By “fragment” is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or more nucleotides or amino acids.

[0056] A “framework (FR) region” or “FR region” refers to amino acid residues that are adjacent to the CDRs in VH, and VL regions. In an embodiment, a FR region refers to the structural FR portions or components of an antibody or binding molecule, namely, FR1, FR2, FR4 and FR4, that positionally and structurally support the three CDR components, namely, CDR1, CDR2 and CDR3 of an antibody polypeptide, as described above.

[0057] By “increase” is meant to alter positively by at least 1%. An increase may be by 5%, 10%, 25%, 30%, 50%, 75%, or even by 100%.

[0058] The terms “isolated,” “purified,” or “biologically pure” refer to material that is free to varying degrees from components which normally accompany it as found in its native state. “Isolate” denotes a degree of separation from original source or surroundings. “Purify” denotes a degree of separation that is higher than isolation. A “purified” or “biologically pure” protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide of this disclosure is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high performance liquid chromatography. The term “purified” can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For a protein that can be subjected to modifications, for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified.

[0059] By “isolated polynucleotide” is meant a nucleic acid that is free of the genes which, in the naturally-occurring genome of the organism from which the nucleic acid molecule of the present disclosure is derived, flank the gene. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; orAtorney Docket No.: 167705-038301 / PCT

[0060] Electronic Deposit Date: May 5, 2026

[0061] into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. In addition, the term includes an RNA molecule that is transcribed from a DNA molecule, as well as a recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequence.

[0062] By an “isolated polypeptide” is meant a polypeptide of the present disclosure that has been separated from components that naturally accompany it. Typically, the polypeptide is isolated when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. In some cases, the preparation is at least 75%, at least 90%, or at least 99%, by weight, a polypeptide of the present disclosure. An isolated polypeptide of the present disclosure may be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid encoding such a polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.

[0063] As used herein, “neonate” refers to an infant that is less than 30 days old. In various embodiments, a neonate is less than 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, or 3 weeks old.

[0064] As used herein, “obtaining” as in “obtaining an agent” includes synthesizing, purchasing, or otherwise acquiring the agent.

[0065] As used herein, the terms “prevent,” “preventing,” “prevention,” “prophylactic treatment” and the like refer to reducing the probability of developing a disease or condition in a subject who does not have, but is susceptible to developing a disease or condition. In some embodiments, the disease is RSV disease.

[0066] By “polypeptide” or “amino acid sequence” is meant any chain of amino acids, regardless of length or post-translational modification. In various embodiments, the post-translational modification is glycosylation or phosphorylation. In various embodiments, conservative amino acid substitutions may be made to a polypeptide to provide functionally equivalent variants, or homologs of the polypeptide. In some aspects the various aspects and embodiments of the present disclosure embrace sequence alterations that result in conservative amino acid substitutions. In some embodiments, a “conservative amino acid substitution” refers to an amino acid substitution that does not alter the relative charge or size characteristics of the protein in which the conservative amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references that compile such methods, e.g. Molecular Cloning: AAtorney Docket No.: 167705-038301 / PCT

[0067] Electronic Deposit Date: May 5, 2026

[0068] Laboratory Manual, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, or Current Protocols in Molecular Biology, F. M.

[0069] Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Non-limiting examples of conservative substitutions of amino acids include substitutions made among amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D. In various embodiments, conservative amino acid substitutions can be made to the amino acid sequence of the proteins and polypeptides disclosed herein.

[0070] By “reduce” is meant to alter negatively by at least 1%. A reduction may be by 5%, 10%, 25%, 30%, 50%, 75%, or even by 100%.

[0071] By “reference” is meant a standard or control condition. In embodiments, the reference is a healthy, uninfected subject (e.g., a neonate not infected with RSV). In some embodiments, a reference is a subject not administered a composition of the present disclosure, or not administered an antibody capable of binding to an RSV antigen.

[0072] A “reference sequence” is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset of or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence. For polypeptides, the length of the reference polypeptide sequence may be at least about 16 amino acids, at least about 20 amino acids, at least about 25 amino acids, about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of the reference nucleic may be at least about 50 nucleotides, at least about 60 nucleotides, at least about 75 nucleotides, about 100 nucleotides, about 300 nucleotides, or any integer thereabout or therebetween.

[0073] By “respiratory syncytial virus fusion (RSV F) protein” is meant a protein with at least about 85% amino acid sequence identity to GenBank Accession No. AAB82436.1, which is provided below, or a fragment thereof capable of mediating membrane fusion.

[0074] >AAB82436.1 fusion protein [human respiratory syncytial virus] MELLIHRLSAIFLTLAINALYLTSSQNITEEFYQSTCSAVSRGYFSALRTGWYTSVITIELSNI KETKCNGTDTKVKLIKQELDKYKNAVTELQLLMQNTPAANNRARREAPQYMNYTINTTKNLNVS ISKKRKRRFLGFLLGVGSAIASGIAVSKVLHLEGEVNKIKNALLSTNKAVVSLSNGVSVLTSKV LDLKNYINNQLLPIVNQQSCRISNIETVIEFQQKNSRLLEINREFSVNAGVTTPLSTYMLTNSE LLSLINDMPITNDQKKLMSSNVQIVRQQSYSIMSIIKEEVLAYVVQLPIYGVIDTPCWKLHTSP LCTTNIKEGSNICLTRTDRGWYCDNAGSVSFFPQADTCKVQSNRVFCDTMNSLTLPSEVSLCNT DIFNSKYDCKIMTSKTDISSSVITSLGAIVSCYGKTKCTASNKNRGI IKTFSNGCDYVSNKGVDAtorney Docket No.: 167705-038301 / PCT

[0075] Electronic Deposit Date: May 5, 2026 TVSVGNTLYYVNKLEGKNLYVKGEPIINYYDPLVFPSDEFDASISQVNEKINQSLAFIRRSDEL LHNVNTGKSTTNIMITTI I IVI IVVLLSLIAIGLLLYCKAKNTPVTLSKDQLSGINNIAFSK

[0076] By “respiratory syncytial virus fusion (RSV F) polynucleotide” is meant a nucleic acid molecule encoding an RSV F protein, as well as the introns, exons, 3' untranslated regions, 5' untranslated regions, and regulatory sequences associated with its expression, or fragments thereof. In embodiments, an RSV F polynucleotide is the genomic sequence, cDNA, mRNA, or gene associated with and / or required for RSV F protein expression. An exemplary RSV F polynucleotide sequence from Homo Sapiens is provided below (GenBank: AFO 13254.1 : 5666-7390):

[0077] >AF013254.1:5666-7390 Human respiratory syncytial virus wildtype strain Bl, complete genome ATGGAGCTGCTGATCCACAGGTTAAGTGCAATCTTCCTAACTCTTGCTATTAATGCATTGTACC TCACCTCAAGTCAGAACATAACTGAGGAGTTTTACCAATCGACATGTAGTGCAGTTAGCAGAGG TTATTTTAGTGCTTTAAGAACAGGTTGGTATACCAGTGTCATAACAATAGAATTAAGTAATATA AAAGAAACCAAATGCAATGGAACTGACACTAAAGTAAAACTTATAAAACAAGAATTAGATAAGT ATAAGAATGCAGTGACAGAATTACAGCTACTTATGCAAAACACACCAGCTGCCAACAACCGGGC CAGAAGAGAAGCACCACAGTATATGAACTATACAATCAATACCACTAAAAACCTAAATGTATCA ATAAGCAAGAAGAGGAAACGAAGATTTCTGGGCTTCTTGTTAGGTGTAGGATCTGCAATAGCAA GTGGTATAGCTGTATCCAAAGTTCTACACCTTGAAGGAGAAGTGAACAAGATCAAAAATGCTTT GTTATCTACAAACAAAGCTGTAGTCAGTCTATCAAATGGGGTCAGTGTTTTAACCAGCAAAGTG TTAGATCTCAAGAATTACATAAATAACCAATTATTACCCATAGTAAATCAACAGAGCTGTCGCA TCTCCAACATTGAAACAGTTATAGAATTCCAGCAGAAGAACAGCAGATTGTTGGAAATCAACAG AGAATTCAGTGTCAATGCAGGTGTAACAACACCTTTAAGCACTTACATGTTAACAAACAGTGAG TTACTATCATTGATCAATGATATGCCTATAACAAATGATCAGAAAAAATTAATGTCAAGCAATG TTCAGATAGTAAGGCAACAAAGTTATTCTATCATGTCTATAATAAAGGAAGAAGTCCTTGCATA TGTTGTACAGCTACCTATCTATGGTGTAATAGATACACCTTGCTGGAAATTACACACATCACCT CTATGCACCACCAACATCAAAGAAGGATCAAATATTTGTTTAACAAGGACTGATAGAGGATGGT ATTGTGATAATGCAGGATCAGTATCCTTCTTTCCACAGGCTGACACTTGTAAAGTACAGTCCAA TCGAGTATTTTGTGACACTATGAACAGTTTGACATTACCAAGTGAAGTCAGCCTTTGTAACACT GACATATTCAATTCCAAGTATGACTGCAAAATTATGACATCAAAAACAGACATAAGCAGCTCAG TAATTACTTCTCTTGGAGCTATAGTGTCATGCTATGGTAAAACTAAATGCACTGCATCCAACAA AAATCGTGGGATTATAAAGACATTTTCTAATGGTTGTGACTATGTGTCAAACAAAGGAGTAGAT ACTGTGTCAGTGGGCAACACTTTATACTATGTAAACAAGCTGGAAGGCAAGAACCTTTATGTAAAtorney Docket No.: 167705-038301 / PCT

[0078] Electronic Deposit Date: May 5, 2026 AAGGGGAACCTATAATAAATTACTATGACCCTCTAGTGTTTCCTTCTGATGAGTTTGATGCATC AATATCTCAAGTCAATGAAAAAATCAATCAAAGTTTAGCTTTTATTCGTAGATCTGATGAATTA CTACATAATGTAAATACTGGCAAATCTACTACAAATATTATGATAACTACAATTATTATAGTAA TCATTGTAGTATTGTTATCATTAATAGCTATTGGTTTGCTGTTGTATTGCAAAGCCAAAAACAC ACCAGTTACACTAAGCAAAGACCAACTAAGTGGAATCAATAATATTGCATTCAGCAAATAG

[0079] By “RSV-binding polypeptide A” is meant an antibody or antigen binding fragment thereof having at least about 85% amino acid sequence identity to a sequence of RSV-binding polypeptide A, wherein the antibody or antigen binding fragment thereof specifically binds to a respiratory syncytial virus (RSV) antigen. In various embodiments, the RSV antigen is an RSV F protein, or a fragment thereof. In embodiments, RSV-binding polypeptide A comprises VH and / or VL CDRs 1-3 of RSV-binding polypeptide A, wherein the VH and / or VL CDRs, and antigen binding fragments thereof, specifically bind to an RSV F protein antigen. In embodiments, the antibody or antigen binding fragment thereof has at least 90%, 93%, 95%, 98%, 99% or 100% amino acid sequence identity to an antibody sequence of RSV-binding polypeptide A. Non-limiting examples of embodiments of RSV-binding polypeptide A include polypeptides capable of binding an RSV antigen described in International Patent Application Publications No. WO2008147196A2, WO2015108967 A2, WO2018160722A1, and WO2020223435A1, the entire contents of each of which are hereby incorporated by reference in their entirety for all purposes. Exemplary heavy chain and light chain sequences for RSV-binding polypeptide A are provided below, where the variable regions are in plain text, the constant domains are in bold, and complementarity determining regions (CDRs), i.e., CDR1, CDR2, and CDR2, are underlined:

[0080] RSV-binding polypeptide A heavy chain (HC):

[0081] QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKF QGRVT I TADE S TDTAYME LS S LRS EDTAM Y YCATETALVVSETYLPHYFDNWGQGTL VTVS SAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLYITREPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPGKAtorney Docket No.: 167705-038301 / PCT

[0082] Electronic Deposit Date: May 5, 2026

[0083] RSV-binding polypeptide A light chain (LC):

[0084] D I QMTQS PS S LSAAVGDRVT I TCQASQDIVNYLNWYQQKPGKAPKLL I YVASNLETGVPSRFSG SGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGL S S P VTK S FNRGEC

[0085] The three CDRs of the RSV-binding polypeptide A VH region are as follows:

[0086] VH CDR1: DYIIN;

[0087] VH CDR2: GIIPVLGTVHYGPKFQ; and

[0088] VH CDR3: ETALVVSETYLPHYFD.

[0089] The three CDRs of the RSV-binding polypeptide A VL region are as follows:

[0090] VL CDR1: QASQDIVNYLN;

[0091] VL CDR2: VASNLET; and

[0092] VL CDR3: QQYDNLPLT.

[0093] The four framework (FR) regions, i.e., FR1, FR2, FR3, and FR4, of RSV-binding polypeptide A are located on either side of each of the CDRs in VH and VL region sequences shown supra. In particular, the four FRs of the RSV-binding polypeptide A VH region are as follows:

[0094] VH FR1 : QVQLVQSGAEVKKPGSSVMVSCQASGGLLE;

[0095] VHFR2: WVRQAPGQGPEWMG;

[0096] VHFR3: GRVTITADESTDTAYMELSSLRSEDTAMYYCAT; and

[0097] VHFR4: WGQGTLVTVSS.

[0098] The four FRs of the RSV-binding polypeptide A VL region are as follows:

[0099] VL FR1: D I QMTQS PS S LSAAVGDRVT I TC;

[0100] VL FR2: WYQQKPGKAPKLLIY;

[0101] VL FR3: GVPSRFSGSGSGTDFSLTISSLQPEDVATYYC; and

[0102] VL FR4: FGGGTKVEIKRTV.

[0103] By “RSV-binding polypeptide A polynucleotide” is meant a nucleic acid molecule encoding at least a fragment of an RSV-binding polypeptide A polypeptide. In an embodiment, the RSV-binding polypeptide A polynucleotide is DNA, RNA, or a hybrid thereof.

[0104] By “RSV-binding polypeptide B” is meant an antibody or antigen binding fragment thereof having at least about 85% amino acid sequence identity to a sequence of RSV-binding polypeptide B, wherein the antibody or antigen binding fragment thereof specifically binds to a respiratory syncytial virus (RSV) antigen. In various embodiments, the RSV antigen is an RSV FAtorney Docket No.: 167705-038301 / PCT

[0105] Electronic Deposit Date: May 5, 2026

[0106] protein, or a fragment thereof. In embodiments, RSV-binding polypeptide B comprises VH and / or VL CDRs 1-3 of RSV-binding polypeptide B, wherein the VH and / or VL CDRs, and antigen binding fragments thereof, specifically bind to an RSV F protein antigen. In embodiments, the antibody or antigen binding fragment thereof has at least 90%, 93%, 95%, 98%, 99% or 100% amino acid sequence identity to an antibody sequence of RSV-binding polypeptide B. Non-limiting examples of embodiments of RSV-binding polypeptide B include polypeptides capable of binding an RSV antigen described in U.S. Patent No. US6955717B2, the entire contents of which are hereby incorporated by reference in their entirety for all purposes. Exemplary heavy chain and light chain sequences for RSV-binding polypeptide B are provided below, where the variable regions are in plain text, the constant domains are in bold, and complementarity determining regions (CDRs), i.e., CDR1, CDR2, and CDR2, are underlined:

[0107] RSV-binding polypeptide B heavy chain (HC):

[0108] QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPS LKSRLT I S KDTS KNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVS SASTKGP SV FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWTVP SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK

[0109] RSV-binding polypeptide B light chain (LC):

[0110] DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGS GSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGT ASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA CEVTHQGL S S P VTK S FNRGEC

[0111] The three CDRs of the RSV-binding polypeptide B VH region are as follows:

[0112] VH CDR1: GFSLSTSGMSVG;

[0113] VH CDR2: DIWWDDKKDYNPSLKS; and

[0114] VH CDR3: SMITNWYFDV.

[0115] The three CDRs of the RSV-binding polypeptide B VL region are as follows:

[0116] VL CDR1 : KCQLSVGYMH;Atorney Docket No.: 167705-038301 / PCT

[0117] Electronic Deposit Date: May 5, 2026

[0118] VL CDR2: DTSKLAS; and

[0119] VL CDR3: FQGSGYPFT.

[0120] The four framework (FR) regions, i.e., FR1, FR2, FR3, and FR4, of RSV-binding polypeptide B are located on either side of each of the CDRs in VH and VL region sequences shown supra. In particular, the four FRs of the RSV-binding polypeptide B VH region are as follows:

[0121] VHFR1: QVTLRESGPALVKPTQTLTLTCTFS;

[0122] VHFR2: WIRQPPGKALEWLA;

[0123] VHFR3: RLTISKDTSKNQVVLKVTNMDPADTATYYCAR; and

[0124] VHFR4: WGAGTTVTVSS.

[0125] The four FRs of the RSV-binding polypeptide B VL region are as follows:

[0126] VL FR1: DIQMTQSPSTLSASVGDRVTITC;

[0127] VL FR2: WYQQKPGKAPKLLIY;

[0128] VL FR3: GVPSRFSGSGSGTEFTLTISSLQPDDFATYYC; and

[0129] VL FR4: FGGGTKLEIKRTV.

[0130] By “RSV-binding polypeptide B polynucleotide” is meant a nucleic acid molecule encoding at least a fragment of an RSV-binding polypeptide B polypeptide. In an embodiment, the RSV-binding polypeptide B polynucleotide is DNA, RNA, or a hybrid thereof.

[0131] By “specifically binds” is meant a compound or antibody that recognizes and binds a polypeptide of the present disclosure, but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample, which naturally includes a polypeptide of the present disclosure.

[0132] Nucleic acid molecules useful in the methods of the present disclosure include any nucleic acid molecule that encodes a polypeptide of the present disclosure or a fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence, but will typically exhibit substantial identity. Nucleic acid molecules useful in the methods of the present disclosure include any nucleic acid molecule that encodes a polypeptide of the present disclosure or a fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence, but will typically exhibit substantial identity. Polynucleotides having “substantial identity” to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. By “hybridize” is meant pair to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under variousAtorney Docket No.: 167705-038301 / PCT

[0133] Electronic Deposit Date: May 5, 2026

[0134] conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399; Kimmel, A. R. (1987) Methods Enzymol. 152:507).

[0135] For example, stringent salt concentration may be less than about 750 mM NaCl and 75 mM trisodium citrate, less than about 500 mM NaCl and 50 mM trisodium citrate, or less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, or at least about 50% formamide. Stringent temperature conditions may include temperatures of at least about 30° C, of at least about 37° C, or of at least about 42° C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In one embodiment, hybridization will occur at 30° C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In another embodiment, hybridization will occur at 37° C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 pg / ml denatured salmon sperm DNA (ssDNA). In still another embodiment, hybridization will occur at 42° C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 pg / ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

[0136] For most applications, washing steps that follow hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps may be less than about 30 mM NaCl and 3 mM trisodium citrate, or less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps may include a temperature of at least about 25° C, of at least about 42° C, or of at least about 68° C. In an embodiment, wash steps will occur at 25° C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In another embodiment, wash steps will occur at 42 C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In another embodiment, wash steps will occur at 68° C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to MolecularAtorney Docket No.: 167705-038301 / PCT

[0137] Electronic Deposit Date: May 5, 2026

[0138] Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.

[0139] By “substantially identical” is meant a polypeptide or nucleic acid molecule exhibiting at least 50% identity to a reference amino acid sequence (for example, any one of the amino acid sequences described herein) or nucleic acid sequence (for example, any one of the nucleic acid sequences described herein). In some cases, such a sequence is at least 60%, 80%, 85%, 90%, 95%, or 99% identical at the amino acid level or nucleic acid to the sequence used for comparison.

[0140] Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, a BLAST program may be used, with a probability score between e'3and e'100indicating a closely related sequence.

[0141] By “perinatal” means the time shortly before and after birth. In various embodiments, a perinatal time period includes the time period from 1 week, 2 weeks, 3 weeks, 1 month, or 2 months before birth to 1 week, 2 weeks, 3 weeks, 1 month, or 2 months after birth.

[0142] By “subject” is meant an animal. The animal can be a mammal. The mammal can be a human or non-human mammal, such as a bovine, equine, canine, ovine, rodent, swine, leporine, or feline. In embodiments, the human is a fetus, neonate, a perinatal animal, or unborn infant.

[0143] Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.

[0144] As used herein, the terms “treat,” treating,” “treatment,” and the like refer to reducing or ameliorating a disorder and / or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.Atorney Docket No.: 167705-038301 / PCT

[0145] Electronic Deposit Date: May 5, 2026

[0146] Unless specifically stated or obvious from context, as used herein, the term “or” is understood to be inclusive. Unless specifically stated or obvious from context, as used herein, the terms “a”, “an”, and “the” are understood to be singular or plural.

[0147] Unless specifically stated or obvious from context, as used herein, the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.

[0148] The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

[0149] Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.

[0150] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 provides a bar graph showing serum levels of a monoclonal antibody at term (E21) and at postnatal day 7 (P7) in Sprague Dawley rat fetuses or postnatal pups delivered the monoclonal antibody by transamniotic fetal immunotherapy (TRAFIT). In FIG. 1, “***” indicates p<0.001. In FIG. 1, “TRAFIT” indicates rat fetuses or postnatal pups administered the monoclonal antibody RSV-binding polypeptide A by TRAFIT, and “Control” indicates rate fetuses or postnatal pups administered a saline solution rather than the monoclonal antibody.

[0151] FIG. 2 provides a bar graph showing lung levels of a monoclonal antibody at term (E21) and at postnatal day 7 (P7) in Sprague Dawley rat fetuses or postnatal pups delivered the monoclonal antibody by transamniotic fetal immunotherapy. In FIG. 2, “***” indicates p<0.001. In FIG. 2, “TRAFIT” indicates rat fetuses or postnatal pups administered the monoclonal antibody RSV-binding polypeptide A by TRAFIT, and “Control” indicates rate fetuses or postnatal pups administered a saline solution rather than the monoclonal antibody.

[0152] DETAILED DESCRIPTION

[0153] The present disclosure features compositions and methods for delivering antibodies to the fetal circulation to be used for reducing the propensity of a fetus or neonate to be infected with RSV and / or reducing the severity of respiratory syncytial virus (RSV) disease in a subject (e.g., a perinatal subject).Atorney Docket No.: 167705-038301 / PCT

[0154] Electronic Deposit Date: May 5, 2026

[0155] The various aspects and embodiments of the present disclosure are based, at least in part, upon the discovery that the amniotic fluid / cavity constitutes a practicable, minimally invasive access window to the fetal circulation. In the Examples provided herein, it is demonstrated that the amniotic cavity / fluid is a route for administration of therapeutic antibodies to the fetus and neonate. The Examples provided herein demonstrate that transamniotic fetal immunotherapy (TRAFIT) involving transamniotic fetal delivery of a clinically relevant recombinant human monoclonal antibody against RSV to a fetus resulted in sustained levels of the antibody in the lungs and serum at term and into the early neonatal period in a rodent model. TRAFIT represents a practical option for reducing the incidence of or treatment of RSV disease in fetuses or neonates.

[0156] The various aspects and embodiments of the present disclosure are also based at least in part on the discovery that the transamniotic route was recently discovered as a minimally invasive means of fetal immunoglobulin administration, however by unclear mechanisms.

[0157] Respiratory Syncytial Virus (RSV)

[0158] The disease burden of RSV in the US and globally cannot be overstated, with many millions of episodes of acute lower respiratory infections and of hospital admissions annually. Overall, RSV is also one of the most common causes of pediatric pneumonia, bronchiolitis, croup, and upper respiratory infections. Infants are particularly vulnerable to RSV, especially before 6 months of age. Besides younger age, the presence of comorbidities such as prematurity, cardiac and / or pulmonary disease, and genetic abnormalities are also risk factors for more severe disease.

[0159] Respiratory syncytial virus (RSV) causes infections of the lungs and respiratory tract. It’s so common that most children have been infected with the virus by age 2. Respiratory syncytial (sin-SISH-ul) virus can also infect adults.

[0160] In adults and older, healthy children, respiratory syncytial virus (RSV) symptoms are mild and typically mimic the common cold. Self-care measures are usually all that’s needed to relieve any discomfort.

[0161] RSV can cause severe infection in some people, including babies 12 months and younger (infants), especially premature infants, older adults, people with heart and lung disease, or anyone with a weak immune system (immunocompromised).

[0162] Prophylaxis against RSV minimizes disease severity and enhance outcomes in infants. Both active and passive immunization methods may be beneficial, though active immunization is considered more likely to be helpful in children older than 6 months. For younger infants, passive immunization is favored. Modified monoclonal antibodies allow for targeted clinicalAtorney Docket No.: 167705-038301 / PCT

[0163] Electronic Deposit Date: May 5, 2026

[0164] applications while structural modifications of the molecule enable manipulation of its pharmacokinetics.

[0165] RSV-Binding Polypeptides

[0166] NIRSEVIMAB® (RSV-binding polypeptide A) is a monoclonal IgGlK antibody intended for RSV prophylaxis which is specific for the prefusion conformation of the F-protein of the virus. RSV-binding polypeptide A contains structural modifications that result in a longer half-life when compared to the RSV-binding protein PALIVIZUMAB™ (RSV-binding polypeptide B), which is an earlier variant of a monoclonal antibody against RSV. For example, a single dose of RSV-binding polypeptide A leads to higher and more sustained levels of RSV neutralizing antibody than five monthly doses of RSV-binding polypeptide B. RSV-binding polypeptide A has been clinically proven to significantly reduce RSV-related infections and hospitalizations. RSV-binding polypeptide A prophylaxis in preterm, late-preterm, and term infants leads to lower incidence and severity of RSV-associated respiratory disease. In August 2023, the Advisory Committee on Immunization Practices (AC IP) of the United States Centers for Disease Control and Prevention (CDC) recommended prophylactic RSV-binding polypeptide A administration for all infants less than 8 months of age who are entering their first RSV season and for all children 8-19 months with increased risk for severe RSV entering their second season.

[0167] Human IgG has a long half-life, of up to one month, which can be extended even further by modifications of its interaction with the FcRn receptor, found in the neonatal endothelium and intestinal lumen, which mediates the uptake and recycling of IgG and prevents lysosomal degradation (Hinton PR, Xiong JM, Johlfs MG, et al. An engineered human IgGl antibody with longer serum half-life. J Immunol 2006; 176 (l):346-56).

[0168] Intra- Amniotic Delivery

[0169] The present disclosure features compositions and methods for delivering antibodies to the fetal circulation to be used for reducing the propensity of a fetus or neonate to be infected with RSV and / or treating respiratory syncytial virus (RSV). The methods involve administering to the amniotic fluid a therapeutically effective amount of an antibody. The antibody is administered by intra-amniotic injection. The method involves the step of administering to the fetus a therapeutic amount of an amount of an antibody sufficient to treat the disease or disorder or symptom thereof, under conditions such that the disease, infection, and / or disorder is treated and / or prevented.Atorney Docket No.: 167705-038301 / PCT

[0170] Electronic Deposit Date: May 5, 2026

[0171] In embodiments, the mother within which the fetus is developing respiratory syncytial virus (RSV). In a particular embodiment, administration of the antibody to the amniotic fluid prevents or reduces transfer of the infection from the mother to the fetus.

[0172] The methods herein include administering to the amniotic fluid surrounding a fetus an effective amount of an antibody, or a composition described herein to produce such effect.

[0173] Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g., opinion) or objective (e.g., measurable by a test or diagnostic method).

[0174] The therapeutic methods of the disclosure (which include prophylactic treatment) in general comprise administration of a therapeutically effective amount of an antibody to the amniotic fluid surrounding a fetus. In embodiments, the fetus is a human fetus. Such treatment will be suitably administered to fetuses, suffering from, having, susceptible to, or at risk for a disease, infection, and / or disorder, or symptom thereof, before and / or after birth. Determination of those subjects “at risk” can be made by any objective or subjective determination by a diagnostic test or opinion of a subject or health care provider (e.g., genetic test, enzyme or protein marker, Marker (as defined herein), family history, and the like).

[0175] In some embodiments, an antibody is administered to the amniotic fluid in an amount of about or at least about 1 pg, 5 pg, 10 pg, 15 pg, 20 pg, 25 pg, 100 pg, 250 pg, 500 pg, 750 pg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1,000 mg. In some embodiments, an antibody is administered to the amniotic fluid in an amount of no more than about 1 pg, 5 pg, 10 pg, 15 pg, 20 pg, 25 pg, 100 pg, 250 pg, 500 pg, 750 pg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1,000 mg.

[0176] In some embodiments, administration of an antibody of the disclosure to the amniotic fluid is associated with a reduction in the intensity, severity, or frequency, or delays the onset of RSV disease and / or infection in a fetus before and / or after birth (i.e., prenatal or perinatal). In some embodiments, administration of an antibody of the disclosure to the amniotic fluid is associated with a reduction in the intensity, severity, or frequency, or delays the onset of RSV disease and / or infection in a newborn baby for 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or 1 year following birth.Atorney Docket No.: 167705-038301 / PCT

[0177] Electronic Deposit Date: May 5, 2026

[0178] In some embodiments, an antibody of the disclosure is administered to the amniotic fluid during a time where the mother of a fetus has an increased chance of exposure to an RS V virus, or where the fetus is expected to be bom during a time where the newborn has an increased chance of exposure to an RSV vims. In some cases, the antibody of the disclosure is administered during a time of an RSV disease epidemic or pandemic or when a fetus is expected to be bom during an RSV disease epidemic or pandemic. In various embodiments, the antibody of the disclosure is administered during a period of time where RSV disease cases are elevated relative to a reference time period or location at a location where the mother of a fetus is present, or is expected to be present. In some cases, the antibody of the disclosure is administered to a fetus expected to be born at a location or to be present at a location during a period of time where RSV disease cases are expected to be elevated at the location relative to a reference time period or location.

[0179] It can be advantageous to administer the antibody at a particular time during the development of the fetus. In embodiments, the antibody is administered prior to, at, after, and / or until about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 25 weeks, 30 weeks, 35 weeks, or 40 weeks of pregnancy. In embodiments, it is advantageous to administer the antibody prior to 20 weeks of pregnancy.

[0180] In embodiments, the trans-amniotic delivery of the antibody to the amniotic fluid results in the presence of and / or an increase in levels of the antibody in the fetal blood plasma. In embodiments, the trans-amniotic delivery of the antibody to the amniotic fluid results in an increase in levels of the antibody in fetal tissues (e.g., thymus, spleen, brain, lung, and / or bone marrow, and / or others, given the presence of the antibody in the fetal blood plasma). In various cases, the antibody is detectable in the blood or a tissue of a newborn baby at 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, or 1 year following birth.

[0181] A skilled practitioner will readily be able to identify suitable methods for detecting and measuring levels of an antibody in the amniotic fluid or in any samples taken from a fetus or from a neonate that received such treatment before birth. For example, ELISA is one example of many techniques available for measuring antibody levels in biological samples such as, to provide non-limiting examples, serum, bone marrow, spleen tissue, thymus tissue, and brain tissue. The biological samples can be collected from the fetus and / or the mother.Atorney Docket No.: 167705-038301 / PCT

[0182] Electronic Deposit Date: May 5, 2026

[0183] Antibodies

[0184] The methods of the disclosure involve administering an antibody capable of binding a respiratory syncytial virus (RSV) protein (e.g., an RSV F protein) to the amniotic fluid surrounding a fetus.

[0185] In embodiments, the antibody compositions of the disclosure contain 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, or 20% (wt / wt) of the antibody.

[0186] Antibodies of all classes can be made by any of the methods known in the art. One method of obtaining antibodies is to immunize suitable host animals with an immunogen and to follow standard procedures for polyclonal or monoclonal antibody production. The immunogen will facilitate presentation of the immunogen on the cell surface. Immunization of a suitable host can be carried out in a number of ways. Nucleic acid sequences encoding a polypeptide of interest, or immunogenic fragments thereof, can be provided to the host in a delivery vehicle that is taken up by immune cells of the host. The cells will in turn express the receptor on the cell surface generating an immunogenic response in the host. Alternatively, nucleic acid sequences encoding the polypeptide, or immunogenic fragments thereof, can be expressed in cells in vitro, followed by isolation of the polypeptide and administration of the polypeptide to a suitable host in which antibodies are raised. In some embodiments the antibody is IgG.

[0187] In embodiments, the antibody contains an Fc domain or a portion thereof that binds to the FcRn receptor. As a non-limiting example, a suitable Fc domain may be derived from an immunoglobulin subclass such as IgG. In some embodiments, a suitable Fc domain is derived from IgGl, IgG2, IgG3, or IgG4. Suitable Fc domains include those derived from human or humanized antibodies.

[0188] Not being bound by theory, improved binding between Fc domain and the FcRn receptor results in prolonged serum half-life. Thus, in some embodiments, a suitable Fc domain comprises one or more amino acid mutations that lead to improved binding to FcRn. Various mutations within the Fc domain that effect improved binding to FcRn are known in the art and can be adapted to practice the various aspects and embodiments of the disclosure. In some embodiments, a suitable Fc domain comprises one or more mutations at one or more positions corresponding to Thr 250, Met 252, Ser 254, Thr 256, Thr 307, Glu 380, Met 428, His 433, and / or Asn 434 of human IgGl. Non-limiting examples of methods for increasing the serum half-life of an immunoglobulin are provided in Longer serum half life: Hinton PR, Xiong JM, Johlfs MG, et al. An engineered human IgGl antibody with longer serum half-life. J Immunol 2006;176 (l):346-56.Atorney Docket No.: 167705-038301 / PCT

[0189] Electronic Deposit Date: May 5, 2026

[0190] Antibodies against a polypeptide of interest may, if desired, be derived from an antibody phage display library. A bacteriophage is capable of infecting and reproducing within bacteria, which can be engineered, when combined with human antibody genes, to display human antibody proteins. Phage display is the process by which the phage is made to ‘display’ antibody proteins on its surface. Genes of antibody gene libraries are inserted into a population of phage. Each phage carries the genes for a different antibody and thus displays a different antibody on its surface.

[0191] Antibodies made by any method known in the art can then be purified from a host cell. Antibody purification methods may include salt precipitation (for example, with ammonium sulfate), ion exchange chromatography (for example, on a cationic or anionic exchange column run at neutral pH and eluted with step gradients of increasing ionic strength), gel filtration chromatography (including gel filtration HPLC), and chromatography on affinity resins such as protein A, protein G, hydroxyapatite, and anti-immunoglobulin.

[0192] Antibodies can be conveniently produced from hybridoma cells engineered to express the antibody. Methods of making hybridomas are well known in the art. The hybridoma cells can be cultured in a suitable medium and spent medium can be used as an antibody source.

[0193] Polynucleotides encoding the antibody of interest can in turn be obtained from the hybridoma that produces the antibody, and then the antibody may be produced synthetically or recombinantly from these DNA sequences. For the production of large amounts of antibody, it is generally more convenient to obtain an ascites fluid. The method of raising ascites generally comprises injecting hybridoma cells into an immunologically naive histocompatible or immunotol erant mammal, especially a mouse. The mammal may be primed for ascites production by prior administration of a suitable composition (e.g., Pristane).

[0194] Pharmaceutical Compositions

[0195] The present disclosure provides compositions comprising an antibody of any class and type for use in methods for reducing the propensity of a fetus or neonate to be infected with RSV and / or reducing the severity of respiratory syncytial virus (RSV) disease. The compositions should be sterile and contain a therapeutically effective amount of the antibody in a unit of weight or volume suitable for administration to a subject.

[0196] Agents (e.g., antibodies) of the present disclosure may be administered within a pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form. Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions toAtorney Docket No.: 167705-038301 / PCT

[0197] Electronic Deposit Date: May 5, 2026

[0198] administer an antibody to amniotic fluid. Therapeutic formulations may be in a liquid form (e.g., liquid solutions or suspensions) or in a solid form (e.g., a lyophilized composition or powder).

[0199] Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions (e.g., NaCl), saline, buffered saline, alcohols, glycerol, ethanol, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, sugars such as mannitol, sucrose, or others, dextrose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrolidone, etc., as well as combinations thereof. The pharmaceutical preparations can, if desired, be mixed with auxiliary agents (e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and / or aromatic substances and the like) which do not deleteriously react with the active compounds or interfere with their activity. In an embodiment, a water-soluble carrier suitable for intravenous administration is used.

[0200] A suitable pharmaceutical composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. A composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.

[0201] Methods well known in the art for making formulations are found, for example, in “Remington: The Science and Practice of Pharmacy” Ed. A. R. Gennaro, Lippincourt Williams & Wilkins, Philadelphia, Pa., 2000. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible, biodegradable lactide polymer, lactide / glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful delivery systems for agents of the present disclosure include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.

[0202] The formulations can be administered to human patients in therapeutically effective amounts. The dosage of an antibody the present disclosure may depend on such variables as the infection being treated, volume of the amniotic cavity, or the nature of a disorder being treated. In an embodiment, the antibody is administered more than once in a given pregnancy.

[0203] A pharmaceutical composition or medicament can be formulated in accordance with the routine procedures as a pharmaceutical composition adapted for administration to human beings. For example, in some embodiments, a composition for intravenous administration typically is a solution in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection. Generally, theAtorney Docket No.: 167705-038301 / PCT

[0204] Electronic Deposit Date: May 5, 2026

[0205] ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water, saline, or dextrose / water. Where the composition is administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0206] Generally, doses of antibodies of the present disclosure will be from about 0.01 mg / kg fetal weight per day to about 1000 mg / kg fetal weight per day and / or per administration. It is expected that doses ranging from about 1 to about 50 mg / kg will be suitable. In an embodiment, an antibody is administered to the amniotic fluid in amounts sufficient to deliver about or at least about 0. Img / kg fetal weight, 0.5mg / kg fetal weight, Img / kg fetal weight, 2 mg / kg feta weight, 3 mg / kg feta weight, 4 mg / kg feta weight, 5 mg / kg feta weight, 6 mg / kg feta weight 7 mg / kg feta weight, 8 mg / kg feta weight, 9 mg / kg feta weight, or 10 mg / kg fetal weight of the antibody to the fetus. In an embodiment, an antibody is administered to the amniotic fluid in amounts sufficient to deliver no more than about Img / kg fetal weight, 2 mg / kg feta weight, 3 mg / kg feta weight, 4 mg / kg feta weight, 5 mg / kg feta weight, 6 mg / kg feta weight 7 mg / kg feta weight, 8 mg / kg feta weight, 9 mg / kg feta weight, or 10 mg / kg fetal weight of the antibody to the fetus. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses) may be employed to the extent that subject tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of an agent and / or compositions of the present disclosure.

[0207] Kits

[0208] The present disclosure provides kits for use in reducing the propensity of a fetus or neonate to become infected with RSV and / or reducing the severity of a respiratory syncytial virus (RSV) disease in a subject (e.g., a fetal subject, a perinatal subject, neonatal subject, and / or a newborn infant). In one embodiment, the kit contains a pharmaceutical composition containing an antibody (e.g., an antibody capable of binding an RSV F antigen) suitable for reducing the propensity of a fetus or neonate to be infected with RSV and / or reducing the severity of RSV disease in a subject. In an embodiment, the kit contains equipment (e.g., hypodermic needles and syringes) to aid in administration of compositions of the present disclosure to amniotic fluid surrounding a fetus.Atorney Docket No.: 167705-038301 / PCT

[0209] Electronic Deposit Date: May 5, 2026

[0210] Optionally, the kit includes directions for administering the pharmaceutical composition to amniotic fluid. In other embodiments, the kit comprises a sterile container which contains the pharmaceutical composition. Such containers can be boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container form known in the art. Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding compositions containing an antibody. The instructions will generally include information about the pharmaceutical composition (e.g., safety information, recommended doses, and the like) and how to administer the composition to the amniotic fluid surrounding a fetus. In other embodiments, the instructions include at least one of the following: description of the antibody; methods for using the enclosed materials; precautions; warnings; indications; clinical or research studies; and / or references. The instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container.

[0211] The practice of the various aspects and embodiments of the present disclosure employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook, 1989); “Oligonucleotide Synthesis” (Gait, 1984); “Animal Cell Culture” (Freshney, 1987); “Methods in Enzymology” “Handbook of Experimental Immunology” (Weir, 1996); “Gene Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987); “Current Protocols in Molecular Biology” (Ausubel, 1987); “PCR: The Polymerase Chain Reaction”, (Mullis, 1994); “Current Protocols in Immunology” (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides of the present disclosure, and, as such, may be considered in making and practicing the present disclosure. Particularly useful techniques for particular embodiments will be discussed in the sections that follow.

[0212] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the assay, screening, and therapeutic methods of the present disclosure, and are not intended to limit the scope of the various aspects and embodiments of the present disclosure.Atorney Docket No.: 167705-038301 / PCT

[0213] Electronic Deposit Date: May 5, 2026

[0214] EXAMPLES

[0215] Example 1: Transamniotic fetal delivery of recombinant human immunoglobulin monoclonal antibodies as a strategy for prevention of neonatal respiratory syncytial virus (RSV) disease

[0216] Modified monoclonal class-G immunoglobulins (IgG) may protect infants from respiratory syncytial virus (RSV), a prevalent disease with particularly high morbidity in newborns. Accordingly, experiments were undertaken to demonstrate that a clinically relevant monoclonal IgG against RSV could be delivered via transamniotic fetal immunotherapy (TRAFIT) to the fetus and remain bioavailable after birth.

[0217] Fetuses (n=75) from five pregnant dams received volume-matched intra-amniotic injections on gestational day 17-18 (E17-18, term=E21-22) of either a United States Food and Drug Administration (FDA) approved and commercially available recombinant human immunoglobulin-Gl -kappa (IgGlK) monoclonal antibody against RSV, namely RSV-binding polypeptide A (NIRSEVIMAB®; n=30; treated group), or of saline (n=45; control group). The saline was administered to control for possible IgGlK interspecies homology. Levels of IgGlK were quantified by ELISA in the serum and lungs at term and on postnatal day of life 7 (P7). Maternal serum samples were also tested. Statistical analyses included two-tailed Fisher’s exact test, Wilcoxon rank sum test, and mixed-effects median regression (p<0.05).

[0218] Overall survival was not significantly different between the two groups (p=0.808) specifically 67% (20 / 30) for the TRAFIT group and 62% (28 / 45) for controls. At the term timepoint, survival was significantly higher in the TRAFIT group (93%, 13 / 14) than in the controls (52%, 15 / 29) (p=0.015). At the P7 timepoint, survival was not significantly different (p=0.066), specifically 44% (7 / 16) for TRAFIT and 81% (13 / 16) for controls.

[0219] The IgGlK monoclonal antibody was detectable on ELISA in the serum at both the term and P7 timepoints, with the TRAFIT group showing significantly higher levels than controls (both p<0.001) (FIG. 1). Median regression controlling for dam of origin did not alter the results at either term or at P7 (p<0.001). IgGlK monoclonal antibody was also detected in the homogenized lung tissue samples at both term and P7, also with the TRAFIT group showing significantly higher levels than controls (both p<0.001) (FIG. 2). Similarly, median regression controlling for dam of origin did not alter these results at either term or P7 (p<0.001). Maternal serum samples did not demonstrate significantly elevated levels of the IgGlK monoclonal antibody between the two groups (p=0.221 at term, and p=0.317 at P7).

[0220] Therefore, TRAFIT using a clinically relevant recombinant human monoclonal antibody against RSV led to sustained levels of the antibody in the serum and lungs of the neonate at termAtorney Docket No.: 167705-038301 / PCT

[0221] Electronic Deposit Date: May 5, 2026

[0222] and into the early neonatal period in a rat model. This demonstrates that TRAFIT is a viable option for preventing RSV disease in newborns. The above results establish TRAFIT as an advantageous viable option for the administration of a monoclonal IgGl antibody to the fetus and neonate to treat or prevent RSV disease that does not have the disadvantage of maternal antibodies against RSV where the maternal antibodies can be highly variable between infants and tend to decline rapidly after birth. TRAFIT may be used as an alternative for mothers with hypersensitivity against an antibody to be administered to a fetus, as well as in select preterm labor scenarios in which the ability to deliver the antibody rapidly to the fetus would be required.

[0223] The following methods were employed in the above Example:

[0224] 1 ntra-amniotic Injections

[0225] Five pregnant Sprague Dawley dams (Charles River Laboratories, Inc., Wilmington, MA) were housed individually under standard dark / light cycles and fed a normal diet ad libitum. On gestational day 17 (E17; term = E21-22), all dams underwent open intra-amniotic injection (see, e.g., Whitlock, et al., J. Pediatr. Surg., 57(l):52-5 (2022), and Whitlock, et al., J. Pediatr. Surg., 57(6): 1004-7 (2022) as previously described). Briefly, general anesthesia was induced with isoflurane (Patterson Veterinary, Greeley, CO) at 4% and maintained at 2-2.5%, all in 100% oxygen. Using sterile technique, a midline laparotomy was performed and the bicomuate uterus was eviscerated. All fetuses (n=75) from the five dams received volume-matched (50 pL) intra-amniotic injections of either a 5.9 mg / mL suspension of a modified, recombinant human immunoglobulin-Gl -kappa (IgGl K) monoclonal antibody against RSV bioequivalent to (i.e., a “generic” form of) NIRSEVIMAB®, an antibody capable of binding an RSV F protein antigen (i.e., RSV-binding polypeptide A) (NIRSEVIMAB®-equivalent; Leinco Technologies, Fenton, MO) (n=30, TRAFIT group) or normal saline (n=45, Control group), the latter to control for possible interspecies homology of IgGlK. Injections were performed using a 33G non-coring needle on a 100 pL syringe (both from Hamilton Company, Reno, NV) introduced into the amniotic cavity under direct visualization by the ventral aspect of the fetus, carefully avoiding the fetus, the placenta, and the umbilical cord. Once the injections were completed, the uterus was returned to the abdomen and the laparotomy was closed in 2 layers with 3-0 VICRYL™ (polyglactin 910) (Ethicon, Somerville, NJ), an absorbable suture, and 5-0 MONOCR YL® (Ethicon), an absorbable monofilament suture, simple running sutures. Animals were allowed to recover, and post-operative analgesia was maintained by sustained release buprenorphine (Zoopharm, Windsor, CO).Atorney Docket No.: 167705-038301 / PCT

[0226] Electronic Deposit Date: May 5, 2026

[0227] Specimen Procurement

[0228] Three dams were randomly assigned to the term timepoint (E21) and the remaining two were assigned to the postnatal day 7 timepoint (P7). Dams were euthanized via chamber-inhaled carbon dioxide while postnatal pups underwent cervical dislocation. For term mothers, maternal serum was collected via sternotomy and division of the great vessels. Next, the midline incision was reopened followed by evisceration of the uterus. The myometrium was incised, and individual fetuses and their gestational membranes were delivered from the uterus “en caul”. The gestational membranes were then ruptured, and the fetus was exposed from the amniotic sac. Fetal blood was obtained via subclavian cut down, allowed to clot, and centrifuged at 2000g for 10 min.; the supernatant serum was then procured. A fetal midline sternotomy was then performed to expose both lungs, which were procured as well. For the postnatal pups, identical serum and lung procurement processes were performed. After procurement, all specimens were placed in 1.5mL tubes and flash frozen using dry ice prior to storage at -80°C.

[0229] ELISA

[0230] All samples were assayed in duplicate using a human IgG Enzyme Linked Immunosorbent Assay (ELISA) specific for the IgGlK monoclonal antibody of NIRSEVIMAB® (RSV-binding polypeptide A) (AntibodySystem, Paris, France). Maternal and offspring serum samples were assayed directly, while lung samples were first homogenized using sterile beads and a shaker (Next Advance, Troy, NY).

[0231] Due to their diminutive sizes, some serum samples at the term timepoint had to be pooled and averaged to reach the minimum volume for ELISA. Specifically, five, four, and two samples from the Control group and two from the TRAFIT group were pooled and analyzed in this manner.

[0232] Statistical Analysis

[0233] Fisher’s exact test was used to compare fetal survival rates between experimental and control groups at term and at P7. The duplicate concentrations of IgGlK monoclonal antibody for each specimen were averaged and standardized by volume (for serum) or weight (for lung tissue). The nonparametric Wilcoxon rank sum test was used to compare ELISA levels (medians, interquartile ranges) between the two groups. A mixed-effects median regression analysis was also implemented to assess the effects of TRAFIT on IgGlK monoclonal antibody levels in lung tissue and serum concentration based on enzyme-linked immunosorbent assay (ELISA) levelsAtorney Docket No.: 167705-038301 / PCT

[0234] Electronic Deposit Date: May 5, 2026

[0235] accounting for fetuses from the same dam (i.e., nested). Two-tailed values of p<0.05 were considered statistically significant. Data analysis was performed using STATA® software version 18 (StataCorp LLC, College Station, Texas), a general-purpose statistical software package for data manipulation, visualization, statistics, and automated reporting.

[0236] Other Embodiments

[0237] From the foregoing description, it will be apparent that variations and modifications may be made to the various aspects or embodiments described herein to adapt it to various usages, antibody classes / types, and conditions. Such embodiments are also within the scope of the following claims.

[0238] The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

[0239] All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.

Claims

Atorney Docket No.: 167705-038301 / PCTElectronic Deposit Date: May 5, 2026CLAIMSWhat is claimed is:

1. A method for reducing the propensity of a fetal or neonatal subject to become infected with a respiratory syncytial virus (RSV) or reducing the severity of a respiratory syncytial virus (RSV) infection or symptoms thereof in a fetal or neonatal subject, the method comprising administering to the amniotic fluid surrounding the subject as a fetus an antigen-binding polypeptide, or antigen-binding fragment thereof, capable of specifically binding an RSV antigen, wherein the subject has or has a propensity to develop a perinatal RSV infection, thereby reducing the propensity of the fetal or neonatal subject to become infected with a respiratory syncytial virus (RSV) or reducing the severity of a respiratory syncytial virus (RSV) infection or symptoms thereof in the fetal or neonatal subject.

2. The method of claim 1, wherein the RSV antigen is an RSV F protein or a fragment thereof.

3. The method of claim 1, wherein the antigen-binding polypeptide, or antigen-binding fragment thereof, is administered by intra-amniotic injection.

4. The method of claim 1, wherein the antigen-binding polypeptide, or antigen-binding fragment thereof, is derived from an IgA, IgD, IgE, IgG, IgM, IgY and / or IgW antibody.

5. The method of claim 1, wherein the antigen-binding polypeptide is a human antibody.

6. The method of claim 1, wherein the antigen-binding polypeptide is RSV-binding polypeptide A or RSV-binding polypeptide B.

7. The method of claim 1, wherein the antigen-binding polypeptide comprises one or more of the following complementarity determining regions (CDRs):VHCDR1: DY I IN;VH CDR2: GI IPVLGTVHYGPKFQ;VHCDR3: ETALVVSETYLPHYFD;VL CDR1: QASQDIVNYLN;Atorney Docket No.: 167705-038301 / PCTElectronic Deposit Date: May 5, 2026VL CDR2: VASNLET; andVL CDR3: QQYDNLPLT.

8. The method of claim 7, wherein the antigen-binding polypeptide comprises an amino acid sequence having at least about 85% identity to the following variable heavy chain (VH) amino acid sequence:QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKF QGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSS.

9. The method of claim 7, wherein the antigen-binding polypeptide comprises an amino acid sequence having at least about 85% identity to the following heavy chain (HC) amino acid sequence:QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKF QGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK SLSLSPGK.

10. The method of claim 7, wherein the antigen-binding polypeptide comprises an amino acid sequence having at least 85% identity to the following variable light chain (VL) amino acid sequence:DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSG S GS GTD FS LT I S S LQ PED VAT Y YCQQ YDNL PLTFGGGTKVE I KRTV.

11. The method of claim 7, wherein the antigen-binding polypeptide comprises an amino acid sequence having at least about 85% identity to the following light chain (LC) amino acid sequence:DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSG SGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSG TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY ACE VTHQGLS S PVTKS FNRGEC.Atorney Docket No.: 167705-038301 / PCTElectronic Deposit Date: May 5, 202612. The method of claim 1, wherein the antigen-binding polypeptide, or antigen-binding fragment thereof, is detectable in the subject at one week following birth.

13. The method of claim 1, wherein the antigen-binding polypeptide, or antigen binding fragment thereof, is detectable in blood and / or lung tissue of the subject at one week following birth.

14. The method of claim 1, comprising administering the antigen-biding polypeptide, or antigen-binding fragment thereof, to the amniotic fluid prior to or during labor.

15. The method of claim 1, wherein a first or sole administration of the antigen-biding polypeptide, or antigen-binding fragment thereof, to the amniotic fluid is made during labor.

16. The method of claim 1, wherein the subject has increased an increased propensity to become infected with RSV, where the increase results from an increase in incidence or predicted increase in incidence of RSV disease at a location where the subject is or will be disposed, and / or during a time period within which the subject is expected to be born.

17. The method of any one of claims 1-16, wherein the subject is a mammal.

18. The method of claim 17, wherein the subject is a human.

19. The method of claim 18, wherein the human subject is a fetus between 7-9 months of term.

20. The method of claim 18, wherein the human subject is a neonate.

21. The method of claim 1, wherein the administration is associated with the presence of and / or an increase in levels of the antigen-binding polypeptide, or antigen-binding fragment thereof, in the serum of the subject.Atorney Docket No.: 167705-038301 / PCTElectronic Deposit Date: May 5, 202622. The method of claim 1, wherein the administration is associated with the presence of and / or an increase in levels of the, antigen-binding polypeptide, or antigen-binding fragment thereof, in a tissue of the subject.

23. The method of claim 1, wherein the method further comprises determining that the mother of the subject is likely to have an adverse response to the antigen-binding polypeptide, or antigen-binding fragment thereof, and the method does not comprise introducing the antigenbinding polypeptide, or antigen-binding fragment thereof, to the blood of the mother of the subject at harmful levels.

24. A kit suitable for use in carrying out the method of claim 1, wherein the kit comprises the antigen-binding polypeptide, or antigen-binding fragment thereof, of claim 1 and a container.